Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.
Videos
Anthony M. Magliocco, MD, discusses the pathologist’s role when treating a patient with melanoma.
Brian Leyland-Jones, MBBS, PhD, gives an overview of a trial that looks at all aspects of sequencing in breast cancer.
Laurie Gaspar, MD, discusses reducing neurotoxicity in small cell lung cancer patients.
James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.
Paul A. Bunn, Jr, MD, explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors (TKIs)
Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses treatment decisions for patients with melanoma.
Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses bulk reduction surgery prior to chemotherapy in patients with stage III ovarian cancer.
Kathy S. Albain, MD, discusses staging versus biology in breast cancer.
Silvia Novello, MD, PhD, discusses the use of chemotherapy in lung cancer.
Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
Minetta Liu, MD, discusses the limitations of radiology in the treatment of patients with metastatic breast cancer.
Russell J. Schilder, MD, discusses the GOG-9929 trial.
Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing immunotherapy and targeted therapy for patients with melanoma.
Giorgio V. Scagliotti, MD, PhD, discusses toxicities related to chemotherapy and surgery in patients with lung cancer.
Naomi B. Boekel, MSc, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses DCIS patients' risk of dying from cardiovascular disease.
David P. Carbone, MD, PhD, describes variations in the accuracy and availability of genetic testing technologies for patients with lung cancer.
Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing in patients with melanoma.
Elizabeth Mittendorf, MD, PhD, discusses the use of peptide vaccines for the treatment of breast cancer.
Don S. Dizon, MD, FACP, Medical Gynecologic Oncologist, Director of the Oncology Sexual Health Clinic, Massachusetts General Hospital, gives an overview of screening for ovarian cancer.
Vernon K. Sondak, MD, talks about personalized medicine when treating patients with melanoma.
Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the risk of pneumonitis from radiation among patients with lung cancer.
Aditya Bardia, MD, MPH, discusses recent advancements in the field of breast cancer.
Grace Dy, MD, associate professor, Department of Medicine, Roswell Park Cancer Institute, discusses the anticipation of side effects from targeted therapies in clinical trials.
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses different plasma testing approaches for patients with lung cancer.
Michael Birrer, MD, PhD, discusses the role of PARP inhibitors in ovarian cancer.
Jeffrey S. Weber, MD, PhD, discusses testing for genetic mutations in patients with melanoma.
Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the role of Afinitor (everolimus) in breast cancer and the BOLERO trials.
Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.
Harvey I. Pass, MD, discusses some of the challenges of treating patients with mesothelioma